Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Capecitabine in Elderly Breast Cancer
NCT00263705Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Jan 2003
- Primary completion
- Aug 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in breast cancer, sponsored by Institut Jules Bordet. Primary endpoint: Rate of patients receiving an acceptable relative dose intensity (RDI) at 18 weeks. Started Jan 2003; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00263705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263705.